Optimizing mifepristone levels for Cushing's patients
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
1. A method for improving efficacy of mifepristone treatment in a patient suffering from Cushing's syndrome, the method comprising:
treating the patient with seven or more daily doses of mifepristone over a period of seven or more days;
testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and
adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL,
with the proviso that the patient is not already suffering from a condition indicated for treatment with mifepristone, thereby improving the efficacy of mifepristone treatment for the patient suffering from Cushing's syndrome.
2. The method of claim 1 , wherein each of the seven or more daily doses of mifepristone are administered orally.
3. The method of claim 1 , wherein the daily dose is at least 300 mg.
4. The method of claim 1 , wherein the daily dose is at least 600 mg.
5. The method of claim 1 , wherein the daily dose is at least 900 mg.
6. The method of claim 1 , wherein the daily dose is at least 1200 mg.
7. The method of claim 1 , wherein the patient is treated with 28 or more daily doses over a period of 28 or more days.
8. The method of claim 1 , wherein the testing is performed by a plasma sampling collection device suitable for detecting mifepristone serum levels.
9. The method of claim 1 , wherein the adjusting step comprises increasing the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.